Acadia Healthcare’s Review by RBC Capital
<p>RBC Capital analysts slightly lowered their price target on <a href='https://financialmodelingprep.com/financial-summary/ACHC'>Acadia Healthcare Company, Inc. (NASDAQ:ACHC)</a> to $93 from $94 while reiterating their Outperform rating.</p>
<p>As the leading provider of high acuity behavioral and addiction treatment services, the analysts continue to believe the company remains uniquely positioned to benefit from multiple tailwinds, which should drive double-digit long-term growth. </p>
<p>The analysts said they came away incrementally more positive on the company’s strategic approach to capitalize on these opportunities with bed additions expected to grow capacity by 7-10% annually. </p>
<p>From 2024 through 2028, management expects revenue to grow at a 9-11% CAGR to $4.5-5.0 billion, or almost double 2022 revenue. Over the same period, management expects to grow adjusted EBITDA at a 10-12% CAGR to $1.06-1.2 billion. Management offered an initial 2023 revenue range of $2.790-2.860 billion, which is slightly ahead of the $2.820 billion consensus at the mid-point.</p>

NASDAQ:ACHC